THE ANTIPROLIFERATIVE RIMINOPHENAZINE AGENTS CLOFAZIMINE AND B669 PROMOTE LYSOPHOSPHOLIPID-MEDIATED INHIBITION OF NA+, K+-ADENOSINE TRIPHOSPHATASE-ACTIVITY IN CANCER CELL-LINES IN-VITRO
- Authors:
- Published online on: May 1, 1994 https://doi.org/10.3892/ijo.4.5.1115
- Pages: 1115-1119
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The effects of the anti-proliferative, phospholipase A(2) (PLA(2))-activating riminophenazine agents, clofazimine and B669, on the Na+, K+-adenosine triphosphatase activity of the FaDu human pharynx squamous carcinoma cell line have been investigated in vitro. At concentrations of 1.25-10 mu g/ml both agents caused dose-related enhancement of PLA(2), as measured by increased release of lysophosphatidylcholine (LPC), and inhibition of Na+, K+-ATPase in intact cells and isolated membrane preparations. The inhibitory effects of both riminophenazines on the Na+, K+-ATPase activity of FaDu cells were mimicked by reagent LPC and prevented by treatment of the cells with the lysophospholipid-neutralizing agents alpha-tocopherol and lysophospholipase. Riminophenazine-mediated inhibition of Na+, K+-ATPase activity was also observed with the HeLa (human cervix epitheloid carcinoma) and T24 (human transitional cell bladder carcinoma) cell lines. The anti-proliferative activity of clofazimine and B669 is therefore probably achieved by lysophospholipid-mediated inactivation of Na+, K+-ATPase.